Patrina Pellett, PhD

OMG!!! Danger! Danger! Danger! Will Robinson! "The rapid advancements in large language models (LLMs) such as ChatGPT have raised concerns about their potential impact on academic integrity. While initial concerns focused on ChatGPT’s writing capabilities, recent updates have integrated DALL-E 3’s image generation features, extending the risks to visual evidence in biomedical research. Our tests revealed ChatGPT’s nearly barrier-free image generation feature can be used to generate experimental result images, such as blood smears, Western Blot, immunofluorescence and so on."

22

7 Comments

As medical communicators, we all use/create images in our communications. Now with AI the medical writers have to be extra careful on the ethics and integrity for images in scientific publications. Read more at our blog below where we have tried to explore this topic. Feel free to comment your experiences. #MedicalWriting

16

Researchers say an AI-powered transcription tool used in hospitals invents things no one ever said. https://lnkd.in/gfZ2Gi5P #transcription #ai #artificialintelligence #healthcare #pharma #digital

3

This is the best article I've seen for SEO in healthcare yet. Terrific stuff from some experts I trust and follow like Virginia Chachati MPharm and Geoff Meakin. Let me know in the comments if you've come across other SEO healthcare articles like this one! https://lnkd.in/gci_tV9t

15

4 Comments

When your content hits all the right SEO marks... 🎯💡 That moment when your blog post ranks, and your client finally realizes that good content isn't just about writing – it's about strategy, research, and a bit of magic ✨✍️ Hard work pays off! 🙌 #ContentWriter #SEO #Marketing #ContentStrategy #FreelancerLife #SwathiWrites #FridayFuns #DigitalMarketing #ContentWriting

5

Future research may refine these dosage recommendations, but for now, starting with 600 mg of NAC and gradually increasing to 2,400-3,000 mg/day seems to be the most effective approach for using NAC for OCD. Read more 👉 https://lnkd.in/gi7DM8Fh #NAC #N-acetylcysteine #OCD #ObsessiveCompulsiveDisorder

1

🔍 Preparing for AI in Medical Writing: Key Focus Areas for Scientific Writers 🚀 With the rise of AI in the medical writing field, particularly for generating Medical Information Letters (MILs), scientific writers need to evolve their approach. Here are some key areas to focus on as AI reshapes how we work in medical information: 1. Embrace AI for Literature Searches & Content Generation: AI can streamline literature searches, data extraction, and even generate first drafts of MILs. Familiarize yourself with NLP tools to automate routine tasks and save valuable time. 2. Sharpen Review and Editing Skills: While AI can draft content, it’s up to us to ensure scientific accuracy and compliance with regulatory standards. Review, verify, and enhance AI outputs for high-quality and regulatory-compliant MILs. 3. Understand AI-Driven Workflow Integration: Optimize your workflow by integrating AI into data gathering, drafting, and content review processes. Collaborate with AI developers to fine-tune tools for your needs and ensure seamless integration. 4. Continuous Learning: Stay updated on the latest AI advancements. Join webinars, attend workshops, and explore AI tools that enhance your skills and improve efficiency. ⚠️ Areas of Concern: A) Regulatory Compliance: AI can miss regulatory nuances, and the responsibility for compliance remains with the human writer. B) Ethical Issues: Be mindful of potential bias in AI-generated content and ensure compliance with data privacy laws like HIPAA or GDPR. C) Over-reliance on AI: AI can assist, but human oversight is essential for ensuring content quality, accuracy, and context. Embrace the future with AI, but remember that critical thinking and human expertise will always be invaluable. 💡 #AI #MedicalWriting #Pharma #MedicalInformation #ScientificWriting #AIMedTech #HealthcareAI #RegulatoryCompliance #DataPrivacy #MedicalLetters

45

Our new course from AI4Healthcare is now fully released. Check out how to 10X your productivity using ChatGPT as a physician. 10X your productivity with ChatGPT https://buff.ly/4e2ksuh Great tips and prompts on how to automate annoying, time consuming tasks that drive burnout and decrease your time with your patients. I hope all of you will enjoy it and please give us any feedback. Looking forward to seeing you in the class. #AI, #GenAI, #machinelearing, #chatGPT, #AI4healthcare

11

There's no need to push good health writers. A simple fact after writing for 2 years in the health space: it's detrimental to business objectives to push health writers for volume. Writing for more than 2-3 hours a day on the same topic is a real struggle for me. If I try and push it, quality is impacted. That's why becoming a large agency with writers being "squeezed-as-lemons" to justify their salary is not my goal. That's why I don't commit to more than 2 articles per week per client (4,000 words). The weekly volume is only an average - some days, I can write more, other days, I can't write anything. If you need more content to be written, get more writers like I do. Show gratitude when they perform well, and understanding when they get sick. Our brains are simply not made to write all day long. We need to sleep on it, then come back at it again with fresh eyes. That's also why we need editors. Just like you, I want to make your health content unique and trustworthy: Adding quotes, expert interviews, real-life experiences... None of which can be produced by AI (which speeds up my research but not my writing). This means it takes a bit more time ... but better content, and ultimately higher chances to get results. Thanks again to my clients who already realized all this and continue to trust me after 2 years of working together 🙏 Val ✍️ PS: Some results below with only 1 article per week in a niche health e-commerce business. -- Hi, I'm Val 👋 ✍️ I help health businesses improve their credibility and visibility on Google. Every blog is unique, infused with genuine empathy and scientific expertise. 📚 I support health and medical writers worldwide to upskill their services with SEO in my Mentoring Program.

20

4 Comments

CDK4/6 inhibitors have revolutionized the treatment of hormone receptor-positive, HER2-negative breast cancer, offering significant improvements in efficacy and patient outcomes. However, their safety profile warrants careful evaluation to ensure optimal patient care. A recent systematic review and meta-analysis of randomized controlled trials (Dec 18, 2024), supplemented by a pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS), revealed critical insights: CDK4/6 inhibitors significantly increase the risk of cardiovascular adverse events (CVAEs), with a Peto odds ratio of 1.86 (95% CI: 1.30-2.68). Commonly observed CVAEs include hypertension (68.07 per 1,000 patients) and QT prolongation (57.15 per 1,000 patients). The pharmacovigilance study identified nine additional CVAEs not reported in RCTs, including arrhythmia, acute coronary syndrome, and intracardiac thrombus. These findings underscore the importance of early identification and management of CVAEs in patients treated with CDK4/6 inhibitors. Clinicians should carefully consider factors such as treatment stage, combination therapies, and patient-specific risks when prescribing these medications. Key takeaway: While CDK4/6 inhibitors remain a critical component of advanced breast cancer therapy, a balanced approach that prioritizes both efficacy and safety is essential. #Oncology #Pharmacovigilance #PatientSafety #CDK46Inhibitors #CardiovascularHealth #EvidenceBasedMedicine

15

1 Comment

I attended the G2 Intelligence webinar "Key Things Labs Need to Know About the FDA’s Final LDT Rule" yesterday. It was very informative. My key takeaways were: 🔸Amended Regulation: The FDA's final rule defines in vitro diagnostic products as those intended for use in disease diagnosis, treatment, and prevention, encompassing reagents, instruments, and systems used with human specimens. 🔸Implementation Timeline: The phased implementation will be over 5 years. It begins with adverse event reporting and complaint handling in the first year, followed by registration and listing, quality system requirements, and submission of high-risk and non-exempt tests over the next four years. 🔸Quality System Requirements: Labs must adhere to design controls, purchasing controls, acceptance activities, and maintain comprehensive records to ensure compliance with the new regulations. 🔸Enforcement Discretion: The FDA has specified scenarios for broad, targeted, and no enforcement discretion, affecting various LDT categories, including 1976-like tests, forensic LDTs, and tests intended for emergencies. 🔸Action Steps for Labs: Labs should remain calm, assess their test menus, understand the final rule, develop compliant policies and procedures, train staff, and consider budget implications, including FDA user fees and quality/regulatory personnel costs. Document, document, document! (Or perhaps it should be “Remain Calm and Document”) Do you have any thoughts (or fears) about implementation of the FDA rule? #LDT #FDA #Regulation #G2Intelligence

2

6 Comments

The spread of dangerous information is proliferating online and is raising many concerns on how the medical and scientific community can help protect our communities, family and friends. This is why the work by science communicators like Unbiased Science and also consortiums like MILE - Medical Information Leaders in Europe and phactMI are becoming so important to providing robust, scientific and medical communications! #medicalinformation #digitalhealth #misinformation #medicalmisinformation

20

This is a step in the right direction! These patients deserve this type of information. Kudos to PAAB for this update! Contact me if you need help navigating the PAAB code. #medicalwriter #medicalwriting #regulatory #healthcomms #pharmamktg #paab #marketing4health

1

Thoughts on this? >> NICE recommends two technologies for tics and Tourette syndrome >> Comment below! >>> lqventures.com #industry40 #IoT #AI #mhealth #healthtech

1

🦾 How can we use #AI to address challenges in rare disease? I’ve seen a lot of chatter online recently about AI and machine learning. Some people are (understandably) skeptical; others see its broad application as undeniably beneficial. In the rare disease space, I view AI as having huge potential. There are over 300 million people living with #RareDiseases worldwide. And there are over 10,000 known rare diseases, with new genetic conditions being discovered all the time. Since these diseases are often not well-understood or have small communities — I recently interviewed Gabby, who is the only known person with her rare disease in the US — rare diseases are hard to diagnosis. People often wait years, sometimes decades, for answers. AI can read patterns in data and identify where undiagnosed patients exist. What groups of symptoms or characteristics physicians should look out for. I recently spoke with Leon van Wouwe, the Chief Innovation Director at Volv Global SA. Volv Global is a world-class leader in applying AI to healthcare with a focus on rare or difficult-to-diagnose diseases. In our interview, we cover the growing onset of artificial intelligence in healthcare, the importance of remembering the human dimension, and how Volv’s inTrigue methodology has already been used to improve diagnostics in Fabry disease and Pompe disease in the UK. Read now 🔗: https://lnkd.in/etpJJMSz #RareDisease #ArtificialIntelligence #PompeDisease #FabryDisease #HealthTech

8

1 Comment

This week, the FDA has issued warning letters to 2 third-party nonclinical testing labs, Mid-Link Testing Company Ltd. and Sanitation & Environmental Technology Institute of Soochow University Ltd., both in China. The FDA cited significant data quality and lab oversight failures. These violations, which include inadequate animal care and inaccurate data recording, raise concerns about the integrity of safety data submitted in device premarket submissions. The labs have 15 days from receiving the FDA notice to notify the FDA of their corrective agencies. Even if a device sponsor uses a third-party lab to conduct nonclinical studies, the sponsor is still responsible to ensure data accuracy. How do you feel about this? What are the pros and cons of using 3rd parties to conduct nonclinical trials?

4

4 Comments